D. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSE:OSTX)

Key Points

• OS Therapies (NYSE:OSTX) has had its "buy" rating reaffirmed by D. Boral Capital, which also set a price target of $20.00 for the stock.
• During recent trading, the stock price decreased to $2.1290 with a market cap of $67.33 million and a PE ratio of -2.48.
• Major institutional investments include Bridgeway Capital Management acquiring a position worth approximately $47,000 and CM Management LLC increasing its stake by 172.6%.

OS Therapies (NYSE:OSTX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $20.00 price objective on the stock.

OS Therapies Stock Performance

Shares of OS Therapies stock traded up $0.08 during trading hours on Wednesday, reaching $2.48. The company's stock had a trading volume of 1,082,813 shares, compared to its average volume of 737,634. The company has a market capitalization of $79.09 million and a P/E ratio of -3.14. The stock's fifty day simple moving average is $1.83 and its two-hundred day simple moving average is $1.73. OS Therapies has a one year low of $1.12 and a one year high of $7.00.

Hedge Funds Weigh In On OS Therapies

A number of hedge funds have recently added to or reduced their stakes in OSTX. Bridgeway Capital Management LLC bought a new stake in OS Therapies during the 2nd quarter worth approximately $47,000. XTX Topco Ltd purchased a new position in shares of OS Therapies during the second quarter valued at approximately $63,000. Finally, CM Management LLC grew its holdings in OS Therapies by 172.6% during the first quarter. CM Management LLC now owns 300,000 shares of the company's stock worth $462,000 after buying an additional 189,956 shares in the last quarter.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.